The European Medicines Agency (EMA) has been informed that Warner Chilcott UK Ltd has withdrawn its application which sought to extend the treatment scope of the hormonal patch, Intrinsa.
Intrinsa is presently authorized for women who have their uterus and both ovaries removed and women who are treated with oestrogen replacement therapies. In August an application was made to the European Medicine’s Agency in order to extend the licence of Intrinsa to broaden the patient population in order to include menopausal women experiencing a low libido but the application has been withdrawn. The reasons for this are as yet unknown beyond the fact that commercial considerations were at the heart of the decision. We will be updating our blog with the latest information as soon as it comes in and reporting on the ever controversial topic of female sexual dysfunction.